This module uses fundamental data of Rakovina Therapeutics to approximate its Piotroski F score. Rakovina Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Rakovina Therapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Rakovina Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rakovina Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Rakovina
Piotroski F Score
Change In Cash
Depreciation
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Begin Period Cash Flow
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Net Tangible Assets
Retained Earnings
Common Stock
Total Current Liabilities
Net Receivables
Total Current Assets
Total Assets
Total Stockholder Equity
Accounts Payable
Cash
Non Current Assets Total
Common Stock Shares Outstanding
Total Liab
Net Invested Capital
Capital Stock
Net Working Capital
Intangible Assets
Ebit
Net Income Applicable To Common Shares
Net Interest Income
Interest Income
Selling General Administrative
Operating Income
Net Income From Continuing Ops
Research Development
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Probability Of Bankruptcy
Net Debt is likely to drop to about 717.4 K in 2025. Long Term Debt is likely to drop to about 1.1 M in 2025.
At this time, it appears that Rakovina Therapeutics' Piotroski F Score is Inapplicable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Rakovina Therapeutics is to make sure Rakovina is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Rakovina Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Rakovina Therapeutics' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Rakovina Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Rakovina Therapeutics in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Net Tangible Assets
3.57 Million
At this time, Rakovina Therapeutics' Net Tangible Assets are fairly stable compared to the past year.
About Rakovina Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rakovina Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rakovina Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rakovina Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.